Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins (RELIEVE)
Primary Purpose
Venous Insufficiency
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Short Catheter Delivery
Sponsored by
About this trial
This is an interventional treatment trial for Venous Insufficiency focused on measuring Perforator Veins, Incompetent Veins, Varicose Veins
Eligibility Criteria
Inclusion Criteria:
- The subject is 18 years of age or older.
- The subject has the presence of incompetent perforator veins measuring > 3 mm in diameter resultant of reflux documented on duplex ultrasound.
- The subject has a CEAP classification of 3, 4, 5 or 6.
- The subject has incompetent perforator veins that are superior to the foot and distal ankle.
- The subject is willing and able to provide appropriate informed consent.
- The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations.
Exclusion Criteria:
- The subject has a history of significant arterial disease.
- The subject is known to be, or suspected to be, pregnant (verified in a manner consistent with institution's standard of care), or is lactating.
- The subject has an Ankle Brachial Index (ABI) of < 0.5
- The subject has occlusive thrombosis in the vein segment to be treated.
- The subject has acute deep vein thrombosis.
- The subject has an active or systemic infection.
- The subject is or was enrolled in another investigational device or drug trial that may interfere with the results of this trial.
Sites / Locations
- Lake Washington Vascular Surgery
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Short Catheter Delviery
Arm Description
Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
Outcomes
Primary Outcome Measures
Primary Effectiveness Objective
The primary objective is to demonstrate the clinical effectiveness (as determined by the absence of flow within the treated incompetent perforated vein [IPV])) of endovenous laser ablation. The number of treated IPVs that are closed at 6 weeks and remain closed at 6 months.
Primary Safety Objective
Safety: Evaluation of occurrence of major device-related adverse events through 6 weeks and the total at 6 months.
Secondary Outcome Measures
Secondary Effectiveness Objective
Effectiveness: The reduction in patient symptoms and the satisfaction of the patient. Patient symptom assessment - CEAP Class, best=0 (no visible or palpable signs of venous disease) & worst=6 (Skin changes in conjunction with active ulceration), VDS, best=0 (asymptomatic) & worst=3 (unable to carry out usual activities even with compression and/or limb elevation) and VCSS, best=0 (absent) & worst=3 (severe). Patient satisfaction - modified Odom's criteria, best=excellent (I am very satisfied with the results of my laser treatment) & worst=poor (I am not satisfied with the results).
Secondary Safety Objective
Safety: Incidence rate of device-related minor adverse events.
Full Information
NCT ID
NCT00565604
First Posted
November 28, 2007
Last Updated
December 8, 2015
Sponsor
Vascular Solutions LLC
1. Study Identification
Unique Protocol Identification Number
NCT00565604
Brief Title
Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins
Acronym
RELIEVE
Official Title
Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins The RELIEVE Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vascular Solutions LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is designed as a prospective, non randomized, single center clinical trial to determine the safety and efficacy of laser ablation of incompetent perforator veins.
Within this clinical evaluation, fifty (50) limbs will be treated with Vari-Lase ®. A duplex ultrasound will verify the presence or absence of incompetent perforator veins (IPV). In addition, the number, diameter and location of the IPVs will be determined. Limbs with IPVs which measure greater than or equal to 3mm in diameter and are located superior to the foot and distal ankle will be considered for entry into the study.
Detailed Description
This is a non randomized, single center clinical investigation, evaluating a total of fifty (50) limbs for the treatment of venous stasis ulcerations using the Vari-Lase laser.
Subjects can be pre-screened utilizing standard of care data for the specified inclusion/exclusion criteria to ensure that they are eligible for treatment in the investigation. All subjects will have a mapping duplex ultrasound study in an Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) approved vascular laboratory. The ultrasound will verify the presence or absence of IPVs. The number, diameter, and location of the IPVs will be mapped. If the subject appears to qualify for the investigation, the subject will then be asked to give his/her written informed consent and be enrolled in the investigation. Upon satisfying all of the inclusion/exclusion criteria the subject will be accepted into the study.
After enrollment, the investigator will document the CEAP class, venous clinical severity score (VCSS), and venous disability score (VDS) in the subject's chart/medical record/source documentation for later transcription on the appropriate case report form. Digital photographs will be taken of the limb to be treated prior to treatment with the subject standing, following a standardized photography regimen.
All enrolled study participants will have a limb treated with the Vari-Lase laser manufactured by VSI. Subject preparation will be the same as for standard greater saphenous vein (GSV) or short saphenous vein, endovenous laser treatment. The initial technical success or failure of the procedure will be noted for each IPV and the pre-diameter of the IPV recorded. Multiple perforators may be treated in a single patient, as well as bilateral procedures allowed.
Follow-up duplex exams will be conducted within the first week of treatment and at 6 months. Follow-up duplex will verify patency vs. closure of IPV, and presence or absence of deep vein thrombosis (DVT) associated with that IPV. The goal is to prove successful closure of the treated IPVs veins as demonstrated by the duplex ultrasound at 6 weeks and show maintained closure of IPVs at 6 months.
Clinical examinations will occur at 2 weeks with an Associated Research Nurse Practitioner, at 6 weeks with the Medical Doctor, and at 6 months with either the Nurse Practitioner or Medical Doctor. At the 6 week visit, photos will be taken of the limb treated and there will be a reclassification of CEAP class, VDS, and VCSS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Insufficiency
Keywords
Perforator Veins, Incompetent Veins, Varicose Veins
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Short Catheter Delviery
Arm Type
Experimental
Arm Description
Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
Intervention Type
Device
Intervention Name(s)
Short Catheter Delivery
Other Intervention Name(s)
Short Catheter 42-0664-01
Intervention Description
For treating incompetent perforator veins of the lower extremities
Primary Outcome Measure Information:
Title
Primary Effectiveness Objective
Description
The primary objective is to demonstrate the clinical effectiveness (as determined by the absence of flow within the treated incompetent perforated vein [IPV])) of endovenous laser ablation. The number of treated IPVs that are closed at 6 weeks and remain closed at 6 months.
Time Frame
6 Months
Title
Primary Safety Objective
Description
Safety: Evaluation of occurrence of major device-related adverse events through 6 weeks and the total at 6 months.
Time Frame
6 Months
Secondary Outcome Measure Information:
Title
Secondary Effectiveness Objective
Description
Effectiveness: The reduction in patient symptoms and the satisfaction of the patient. Patient symptom assessment - CEAP Class, best=0 (no visible or palpable signs of venous disease) & worst=6 (Skin changes in conjunction with active ulceration), VDS, best=0 (asymptomatic) & worst=3 (unable to carry out usual activities even with compression and/or limb elevation) and VCSS, best=0 (absent) & worst=3 (severe). Patient satisfaction - modified Odom's criteria, best=excellent (I am very satisfied with the results of my laser treatment) & worst=poor (I am not satisfied with the results).
Time Frame
6 Months
Title
Secondary Safety Objective
Description
Safety: Incidence rate of device-related minor adverse events.
Time Frame
6 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
The subject is 18 years of age or older.
The subject has the presence of incompetent perforator veins measuring > 3 mm in diameter resultant of reflux documented on duplex ultrasound.
The subject has a CEAP classification of 3, 4, 5 or 6.
The subject has incompetent perforator veins that are superior to the foot and distal ankle.
The subject is willing and able to provide appropriate informed consent.
The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations.
Exclusion Criteria:
The subject has a history of significant arterial disease.
The subject is known to be, or suspected to be, pregnant (verified in a manner consistent with institution's standard of care), or is lactating.
The subject has an Ankle Brachial Index (ABI) of < 0.5
The subject has occlusive thrombosis in the vein segment to be treated.
The subject has acute deep vein thrombosis.
The subject has an active or systemic infection.
The subject is or was enrolled in another investigational device or drug trial that may interfere with the results of this trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Pepper, MD
Organizational Affiliation
Lake Washington Vascular Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lake Washington Vascular Surgery
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98004
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins
We'll reach out to this number within 24 hrs